文献速递贫血与红细胞疾病

重型β地中海贫血:高钙尿症的患病率、危险因素及临床后果

Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.
PubMed 文献 · Br J Haematol · 2022-06-29

在费拉拉地中海贫血中心随访的176例成年重型β地中海贫血患者中,高钙尿症(24小时尿钙≥4 mg/kg/天)患病率为69.3%(女性52.5%)。高钙尿症患者使用地拉罗司的比例更高(47.5% vs 29.6%,p<0.05),且肾结石发生率更高(14.8% vs 3.7%,p<0.05)。

要点

  • 成年重型β地中海贫血患者高钙尿症患病率为69.3%。
  • 高钙尿症患者使用地拉罗司比例高于尿钙正常患者(47.5% vs 29.6%)。
  • 高钙尿症患者肾结石发生率高于尿钙正常患者(14.8% vs 3.7%)。

核心结论

  • 高钙尿症是经充分治疗的成年重型β地中海贫血患者的常见并发症。
  • 高钙尿症患病率在地拉罗司使用者中增加,而血红蛋白水平或钙补充剂不起作用。
  • 相当比例的高钙尿症患者发生肾结石。

研究设计与样本

  • 研究纳入在费拉拉地中海贫血中心随访的176例成年重型β地中海贫血患者。
  • 高钙尿症定义为24小时尿样中尿钙≥4 mg/kg/天。
  • 收集了病史、生化和影像学数据。

主要发现

  • 高钙尿症患病率为69.3%(女性52.5%)。
  • 高钙尿症患者使用地拉罗司的比例高于尿钙正常患者(47.5% vs 29.6%,p<0.05)。
  • 高钙尿症患者血浆甲状旁腺激素水平低于尿钙正常患者(24.1 ± 10.4 vs 30.1 ± 13.2 pg/ml,p<0.05)。
  • 高钙尿症患者血磷水平低于尿钙正常患者(3.6 ± 0.5 vs 3.8 ± 0.7 mg/dl,p<0.05)。
  • 高钙尿症患者血钙水平高于尿钙正常患者(9.6 ± 0.4 vs 9.4 ± 0.4 mg/dl,p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regular transfusion and chelation therapy produces increased life expectancy in thalassaemic patients who may develop new complications. Since few data are available regarding hypercalciuria in β-thalassaemia major (TM), the aim of our study was to evaluate its prevalence, risk factors and clinical consequences. We enrolled 176 adult TM patients followed at the Center of Thalassemia of Ferrara. Hypercalciuria was defined by a calciuria of 4 mg/kg/day or more in a 24-h urine sample. Anamnestic, biochemical and radiological data were collected. Hypercalciuria prevalence was reported in 69.3% of patients (females 52.5%). Hypercalciuric (HC) patients used deferasirox (DFX) more often than normocalciuric (NC) patients (47.5% vs 29.6%; p < 0.05). In HC subjects plasma parathyroid hormone (PTH) (24.1 ± 10.4 vs 30.1 ± 13.2 pg/ml) and phosphate levels (3.6 ± 0.5 vs 3.8 ± 0.7 mg/dl) were lower, whereas serum calcium (9.6 ± 0.4 vs 9.4 ± 0.4 mg/dl) and urinary 24-h phosphaturia (0.9 ± 0.4 vs 0.6 ± 0.3 g/day) were higher as compared to NC patients (p < 0.05 for all comparisons). Supplementation with oral calcium and cholecalciferol was similar between the groups. A higher rate of kidney stones was present in HC (14.8%) versus NC patients (3.7%) (p < 0.05). Hypercalciuria is a frequent complication in adequately treated adult TM patients. Hypercalciuria prevalence is increased in DFX users whereas haemoglobin level or calcium supplements play no role. A significant proportion of HC patients developed kidney stones.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Aliberti L, Gagliardi I, Gamberini MR, et al. Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria. Br J Haematol. 2022. PMID: 35768889. doi:10.1111/bjh.18345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。